Journal Watch · Science Translational Medicine · 2026
CD4<sup>+</sup> T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis.
Our results establish preferential CD4<sup>+</sup> T cell reactivity to EBV late lytic antigens as a key feature of MS, providing a framework for developing EBV-targeted therapies, including vaccines and antivirals.
TL;DR
Our results establish preferential CD4<sup>+</sup> T cell reactivity to EBV late lytic antigens as a key feature of MS, providing a framework for developing EBV-targeted therapies, including vaccines and antivirals.
Key findings
- Anti-CD20 therapy initiation in treatment-naïve participants reduced these responses, a finding validated in an independent cohort, and eliminated viral shedding in saliva.
- Our results establish preferential CD4<sup>+</sup> T cell reactivity to EBV late lytic antigens as a key feature of MS, providing a framework for developing EBV-targeted therapies, including vaccines and antivirals.
What they did
In contrast, the Epstein-Barr nuclear antigen 1 (EBNA1) primarily activated CD8<sup>+</sup> T cells. EBV-specific CD4<sup>+</sup> T cell responses were twofold higher in individuals with untreated MS compared with healthy controls, whereas responses to other herpesviruses remained similar.
Full abstract (original)
Background: Multiple sclerosis (MS) pathogenesis is linked to Epstein-Barr virus (EBV), but the underlying immune mechanisms remain unclear. Using an optimized T cell assay, we demonstrate that CD4<sup>+</sup> T cells from individuals with MS predominantly target EBV viral particle components, specifically the late lytic capsid and glycoprotein antigens, rather than latent antigens.
What they did: In contrast, the Epstein-Barr nuclear antigen 1 (EBNA1) primarily activated CD8<sup>+</sup> T cells. EBV-specific CD4<sup>+</sup> T cell responses were twofold higher in individuals with untreated MS compared with healthy controls, whereas responses to other herpesviruses remained similar.
Results & conclusions: Anti-CD20 therapy initiation in treatment-naïve participants reduced these responses, a finding validated in an independent cohort, and eliminated viral shedding in saliva. Our results establish preferential CD4<sup>+</sup> T cell reactivity to EBV late lytic antigens as a key feature of MS, providing a framework for developing EBV-targeted therapies, including vaccines and antivirals.
Abstract © the authors / Science Translational Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1126/scitranslmed.adz6566 · PubMed 42455903.
Why it matters for pharma & biotech
- Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: vaccines
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Science Translational Medicine study find?
Our results establish preferential CD4<sup>+</sup> T cell reactivity to EBV late lytic antigens as a key feature of MS, providing a framework for developing EBV-targeted therapies, including vaccines and antivirals.
What type of study is this?
It is a cohort / observational clinical study, published in Science Translational Medicine in 2026. In contrast, the Epstein-Barr nuclear antigen 1 (EBNA1) primarily activated CD8<sup>+</sup> T cells.
Where can I read the original paper?
The original is at the publisher via DOI 10.1126/scitranslmed.adz6566. PubMed ID: 42455903. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cd4-lt-sup-gt-lt-sup-gt-t-cells-reactive-to-epstein-barr-virus-late-lyti-dz6566/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides